N-acetyltransferase-2 polymorphism in Parkinson's disease: The Rotterdam study

Journal of Neurology Neurosurgery and Psychiatry

Volumn 67, Issue 4, 1999, Pages 518-520

  Harhangi, B Sanjay ^a   Oostra, Ben A ^a   Heutink, Peter ^a   Van Duijn, Cornelia M ^a   Hofman, Albert ^a   Breteler, Monique M B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Genetics; N acetyltransferase 2; Parkinson's disease

Indexed keywords

ACYLTRANSFERASE;

ADULT; AGED; AGING; ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 0032837459     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.67.4.518     Document Type: Article

References (19)

1. de Rijk MC, Tzourio C, Breteler MMB, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:10-5.
2. de Rijk MC, Breteler MMB, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995;45:2143-6.
3. Landi MT, Ceroni M, Martignoni E, et al. Gene-environment interaction in Parkinson's disease. The case of CYP2D6 gene polymorphism. Acta Neurol 1996;69:61-72.
4. Tanner CM. Epidemiology of Parkinson's disease. Neurol Clin 1992;10:317-29.
5. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996;47:161-70.
6. Bandmann O, Marsden CD, Wood NW. Genetic aspects of Parkinson's disease. Mov Disord 1998;13:203-11.
7. Daly AK, Cholerton S, Armstrong M, et al. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 1994;102: 55-61.
8. Bandmann O, Vaughan J, Holmans P, et al. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 1997;350:1136-9.
9. Blum M, Demierre A, Grant DM, et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991;88:5237-11.
10. Hickman D, Risch A, Buckle V, et al. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 1994;297:441-5.
11. Blum M, Grant DM, McBride W, et al. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990;9:193-203.
12. Seidler A, Hellenbrand W, Robra BP, et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996;46:1275-84.
13. Nicholl DJ, Bennett P. Acetylator genotype and Parkinson's disease. Lancet 1998;351:141-2.
14. Hofman A, Grobbee DE, de Jong PTVM, et al. Determinants of disease and disability in the elderly: the Rotterdam elderly study. Eur J Epidemiol 1991;7:403-22.
15. Bell DA, Taylor JA, Butler MA, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993;14:1689-92.
16. Lin HJ, Han CY, Lin BK, et al. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites:application to metabolic epidemiology. Am J Hum Genet 1993;52:827-34.
17. Ray-Chaudhuri K, Smith C, Gough AC, et al. Debrisoquine hydroxylase gene polymorphism in Parkinson's disease and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1995;58:109.
18. Weber WW, Hein DW. N-acetylation pharmacogenetics Pharmacol Rev 1985;37:25-79.
19. Paolini M. Acetylator genotype and Parkinson's disease Lancet 998;351:141.